Dataset Information

Spectral histopathology supported laser capture microdissection and quantitative proteome analysis of diffuse malignant mesothelioma

ABSTRACT: FTIR based spectral histopathology was used for label-free classification of tumor tissue sections. The regions of interest were identified and annotated with high spatial resolution. The spatial information was used for automated laser capture microdissection of relevant tissue areas. Subsequently, the collected tissue samples were analyzed using quantitative proteomics. This novel approach for precise sample collection in clinical studies was applied to differentiate epitheloid and sarcomatoid subtypes of diffuse malignant mesothelioma.

INSTRUMENT(S): LTQ Orbitrap Elite

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Lung, Meso-epithelium, Pleura

DISEASE(S): Malignant Mesothelioma

SUBMITTER: Thilo Bracht

LAB HEAD: Barbara Sitek

PROVIDER: PXD004818 | Pride | 2017-03-31

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 135

Publications

Spatial and molecular resolution of diffuse malignant mesothelioma heterogeneity by integrating label-free FTIR imaging, laser capture microdissection and proteomics.

Großerueschkamp Frederik F Bracht Thilo T Diehl Hanna C HC Kuepper Claus C Ahrens Maike M Kallenbach-Thieltges Angela A Mosig Axel A Eisenacher Martin M Marcus Katrin K Behrens Thomas T Brüning Thomas T Theegarten Dirk D Sitek Barbara B Gerwert Klaus K

Scientific reports 20170330

Diffuse malignant mesothelioma (DMM) is a heterogeneous malignant neoplasia manifesting with three subtypes: epithelioid, sarcomatoid and biphasic. DMM exhibit a high degree of spatial heterogeneity that complicates a thorough understanding of the underlying different molecular processes in each subtype. We present a novel approach to spatially resolve the heterogeneity of a tumour in a label-free manner by integrating FTIR imaging and laser capture microdissection (LCM). Subsequent proteome ana ...[more]

PMID: 28358042

Similar Datasets

Project description:During pregnancy, the Zika virus (ZIKV) can be vertically transmitted, causing Congenital Zika Syndrome (CZS) in fetuses. ZIKV infection in early gestational trimesters increases the chances to develop CZS. This syndrome involves several pathologies with a difficult diagnosis, which usually occurs in the postnatal stage. In this work, we aim to identify biological processes and molecular pathways related to CZS development and propose a series of putative protein and metabolite biomarkers for CZS prognosis in early pregnancy trimesters. Twenty-five serum samples of pregnant women were analyzed. For biological analysis, samples were separated into 3 biological groups composed of a control group of healthy pregnant women and two groups of ZIKV-infected pregnant women bearing non- microcephalic and microcephalic fetuses. Control and ZIKV-infected groups - without microcephalic fetuses - were subdivided into healthy and Cognitive Developmental Delay (CDD) newborns for biomarker analysis. We detected over 1,000 proteins and 500 metabolites by bottom-up proteomics and untargeted metabolomics, respectively. Statistical approaches - (t-Student, Limma, ANOVA, and DIABLO) - were applied to find CZS differentially abundant proteins (DAP) and metabolites (DAM). Enrichment analysis (i.e., biological processes and molecular pathways) of the DAP and the DAM allowed us to identify the ECM organization and proteoglycans, amino acid metabolism, and arachidonic acid metabolism as signatures in the CZS development. Five proteins and four metabolites were selected as CZS biomarkers candidates. The protein-based model indicated superior performance values for the Vitamin K-dependent protein S, Selenoprotein P, Inter-alpha- trypsin inhibitor heavy chain H2, Kallistatin, and Protein Z-dependent protease inhibitor proteins. Furthermore, the metabolite-based model was able to predict CZS with a probability of 90%. Serum multi-omics analysis led us to propose for further studies nine potential biomarkers for CZS early prognosis with high sensitivity and specificity.

			Action	DRS
	OEI12707.mgf	Mgf
	OEI12707.mzid.gz	Mzid
	OEI12707.pride.mgf.gz	Mgf
	OEI12707.pride.mztab.gz	Mztab
	OEI12707.raw	Raw